Preoperative and Intraoperative Risk Factors for Prolonged Intensive Care Unit Stay After Aortic Arch Surgery
Qian Lei(University of Electronic Science and Technology of China), Lihuan Li(Peking Union Medical College Hospital), Hongwen Ji(Chinese Academy of Medical Sciences & Peking Union Medical College), Mu Jin(Capital Medical University), Lei Chen(Zhuzhou Central Hospital), Qinjun Yu(Chinese Academy of Medical Sciences & Peking Union Medical College), Weiping Cheng(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 13
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934